<DOC>
	<DOC>NCT01437722</DOC>
	<brief_summary>The purpose in this clinical study is to determine the efficacy of SPL7013 Gel for the prevention of recurrence of bacterial vaginosis.</brief_summary>
	<brief_title>Dose-ranging Study of SPL7013 Gel for the Prevention of Bacterial Vaginosis (BV)</brief_title>
	<detailed_description />
	<mesh_term>Vaginal Diseases</mesh_term>
	<mesh_term>Vaginosis, Bacterial</mesh_term>
	<criteria>Women aged 1845 years with a history of recurrent BV, defined as at least 3 documented episodes in the previous 12 months (including the current episode). Current episode of BV as defined by subjectreported symptoms and Amsel's Criteria Otherwise healthy No active STIs and/or current UTI Previous exposure to SPL7013 Gel A Papanicolaou (Pap) smear result considered to be clinically significant (ie, high grade cervical intraepithelial squamous lesions [HSIL] on cytology or cervical intraepithelial neoplasia [CIN] grades of CIN2 or CIN3 on histology) in the previous 2 years or in accordance with local treatment guidelines.</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>October 2013</verification_date>
	<keyword>BV</keyword>
	<keyword>Bacterial vaginosis</keyword>
	<keyword>recurrent</keyword>
	<keyword>SPL7013 Gel</keyword>
	<keyword>VivaGel</keyword>
</DOC>